Record mula sa primary source
Decision-gradePag-apruba ng FDA
Nakuha ng Eli Lilly Ebglyss ang pag-apruba ng FDA para sa 8-linggong maintenance dosing sa atopic dermatitis
Nakasaad sa dokumento na inaprubahan ng U.S. FDA ang Ebglyss (lebrikizumab-lbkz) para sa isang maintenance dose tuwing walong linggo sa moderate-to-severe atopic dermatitis. Ina-update nito ang aprubadong dosing regimen para sa asset. Walang ibang regulatory outcomes o petsa ang binago ng tekstong ito.
Mahahalagang fact
- Na-file
- Ago 5, 2026, 11:05 AM
- Kaganapan
- Pag-apruba ng FDA
- Direksyon
- Positibo
- Kumpanya
LLYEli Lilly- Asset
- lebrikizumab
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 q226lillysalesandearningsp.htm EX-99.1 Document August 5, 2026 For release: Immediately Refer to: Megan MacCauley; maccauley_megan@lilly.com (Media) Mike Czapar; czapar_michael_c@lilly.com (Investors) Lilly reports second-quarter 2026 financial results, raise s full-year guidance, and highlights continued growth and pipeline progress • Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. • Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis. Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&D charges compared to $0.14 in Q2 2025. • Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion and raised underlying non-GAAP EP